Reports to VAERS, self-reports in CDC's V-safe app, federal compensation claims, lawsuits and regulators' findings are different kinds of evidence. This tracker keeps them apart: every number carries its source, its denominator (or the fact that it has none), its date range and what it can and cannot show. There is no single "injuries" total here because no honest one exists.
5Source datasets
9,226Data points
7Court cases
19Records
Charts
COVID-19 vaccine reports to VAERS, by month received
None — these are counts of reports, not rates. VAERS does not know how many people were vaccinated.
Date range
Dec 1, 2020 – Oct 30, 2026
Evidence class
Adverse-event report (unverified)
Caveat: VAERS reports are unverified: anyone can file one, they may be incomplete, coincidental or duplicated, and a report does not show that a vaccine caused the event. VAERS has no denominator of people vaccinated, so these counts are not rates.
None — counts of reports. A report stating a death or hospitalization is not a finding that the vaccine caused it.
Date range
Dec 1, 2020 – Oct 30, 2026
Evidence class
Death reportedLife-threatening event reportedHospitalization reportedPermanent disability reported
Caveat: VAERS reports are unverified: anyone can file one, they may be incomplete, coincidental or duplicated, and a report does not show that a vaccine caused the event. VAERS has no denominator of people vaccinated, so these counts are not rates. One report can carry more than one outcome category (for example hospitalized and life-threatening), so outcome rows overlap and must not be added together.
Caveat: VAERS reports are unverified: anyone can file one, they may be incomplete, coincidental or duplicated, and a report does not show that a vaccine caused the event. VAERS has no denominator of people vaccinated, so these counts are not rates. A report is counted under every listed symptom term it contains, so symptom rows overlap. A coded symptom term is what the reporter or coder entered, not a confirmed diagnosis.
None — counts of reports. For FDA's per-dose incidence estimate, see the FDA labeling record below.
Date range
Jan 1, 1990 – Oct 30, 2026
Evidence class
Adverse-event report (unverified)
Caveat: VAERS reports are unverified: anyone can file one, they may be incomplete, coincidental or duplicated, and a report does not show that a vaccine caused the event. VAERS has no denominator of people vaccinated, so these counts are not rates. A report is counted under every listed symptom term it contains, so symptom rows overlap. A coded symptom term is not a confirmed diagnosis.
None — counts of petitions. Petitions are usually adjudicated two to three years after filing, so a year's filings and adjudications are different petitions.
Date range
Oct 1, 2005 – Sep 1, 2026
Evidence class
Compensation claim filedClaim compensatedClaim dismissed or denied
Caveat: VICP figures are petitions and payments, not injury counts. HRSA states that about 60 percent of compensation comes from negotiated settlements in which HHS did not conclude the vaccine caused the injury, and that being compensated does not necessarily mean the vaccine caused the alleged injury. COVID-19 vaccines are not covered by the VICP.
Counts of adjudicated petitions. HRSA lists CDC doses distributed (not administered) for each vaccine; they appear in the rows behind this chart.
Date range
Jan 1, 2006 – Dec 31, 2024
Evidence class
Claim compensatedClaim dismissed or denied
Caveat: Only concessions and court decisions involve a determination for the petitioner; HRSA says settlements are not a finding that the vaccine caused the injury. Many dismissals are procedural.
9,552,127 participants with at least one check-in in this file (self-enrolled; not representative of everyone vaccinated). Percentages use this base.
Date range
Dec 14, 2020 – Aug 1, 2022
Evidence class
Self-reported health eventMedical care reportedHospitalization reported
Caveat: V-safe entries are self-reported, unverified and not diagnoses. Reporting medical care or a missed workday after vaccination does not show the vaccine caused it. Free-text entries are not used or republished.
13,861 participants with at least one check-in in this file (self-enrolled; not representative of everyone vaccinated). Percentages use this base.
Date range
Jun 20, 2022 – Aug 1, 2022
Evidence class
Self-reported health eventMedical care reportedHospitalization reported
Caveat: V-safe entries are self-reported, unverified and not diagnoses. Reporting medical care or a missed workday after vaccination does not show the vaccine caused it. Free-text entries are not used or republished.
None — counts of claims. Bars are separate counts, not parts of one total; denial reasons are subsets of “Denied”.
Date range
Mar 1, 2020 – Oct 1, 2026
Evidence class
Compensation claim filedClaim compensatedClaim dismissed or denied
Caveat: CICP figures are claims and program decisions. Filing a claim is an allegation, a denial is often procedural (missing records, missed deadline), and a payment is a program determination under the CICP's rules, not a scientific finding that a countermeasure caused an injury. Most COVID-19 claims were still awaiting records or review on the as-of date.
None — counts of compensated claims and dollars paid.
Date range
Oct 1, 2009 – Mar 1, 2026
Evidence class
Claim compensated
Caveat: A CICP payment is a program determination that a covered injury occurred under the program's standard; it is not a scientific estimate of risk, and the table's as-of date can lag the summary page.
Every row is one published count from one source table. Rows from different tables or systems should not be added together: categories overlap within VAERS, and VAERS, V-safe and compensation programs count different things.
Source table
Evidence class
Product
Breakdown
Period
Count
Denominator
Rev.
Choose filters and press Filter to load rows.
Litigation, regulatory findings and public records
litigationLawsuit allegationpending
Florida v. Pfizer Inc. and Albert Bourla (COVID-19 vaccine marketing)
Court: Circuit Court of the Nineteenth Judicial Circuit in and for St. Lucie County, Florida (Civil Division) · Docket: Not shown on the filed complaint (e-filing no. 258276669)
The complaint alleges Pfizer and its chief executive deceived Florida consumers by assuring them the vaccine posed no material safety risks while Pfizer knew of data on myocarditis and pericarditis in minors, had reason to expect harms in early pregnancy, and held thousands of reports of other adverse events; and by telling consumers vaccination would stop transmission when the vaccine's effect on transmission had not been tested (complaint ¶¶ 7–8, 11–13). The state brings the action under sections 501.207(1)(a) and (1)(b), Florida Statutes.
These are the state's allegations. No court has ruled on them.
Lawsuit allegation Complaint e-filed in St. Lucie County circuit court (filing no. 258276669). document
Revision 2 · status as of Oct 6, 2026 · last checked Nov 11, 2026
litigationLawsuit allegationpending
McInish and Fible v. HRSA (challenge to the Countermeasures Injury Compensation Program)
Court: U.S. District Court for the District of Columbia · Docket: 1:25-cv-04476
Two women who report debilitating injuries after Pfizer and Moderna vaccines allege the CICP violates due process and equal protection by leaving people injured by covered countermeasures without an adequate remedy.
These are the plaintiffs' allegations; the case is pending.
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
litigationLawsuit allegationon appeal
Kansas v. Pfizer Inc. (COVID-19 vaccine marketing)
Court: District Court of Thomas County, Kansas; removed to U.S. District Court for the District of Kansas (No. 6:24-cv-01128); appeal in the U.S. Court of Appeals for the Tenth Circuit (No. 25-3085) · Docket: D. Kan. 6:24-cv-01128; 10th Cir. 25-3085
Kansas alleges Pfizer misrepresented the vaccine's safety and effectiveness, including its safety in pregnancy and the risk of myocarditis, in violation of the Kansas Consumer Protection Act.
These are the state's allegations. The federal rulings so far concern which court hears the case, not whether the allegations are true.
Lawsuit allegation Kansas files suit in Thomas County District Court (date as reported; the state-court filing is not online). news report
Other public record Pfizer removes the case to federal court (D. Kan. No. 6:24-cv-01128). docket
Court ruling The federal court grants Kansas's motion to send the case back to state court (a procedural ruling on jurisdiction). news report
Other public record Tenth Circuit dockets Pfizer's appeal (No. 25-3085); Kansas is the appellee. docket
Revision 2 · status as of Oct 6, 2026 · last checked Nov 11, 2026
litigationLawsuit allegationon appeal
Texas v. Pfizer Inc. (COVID-19 vaccine efficacy claims)
Court: Lubbock County district court; removed to U.S. District Court for the Northern District of Texas (No. 5:23-cv-00312); appeal in the U.S. Court of Appeals for the Fifth Circuit (No. 25-10182) · Docket: N.D. Tex. 5:23-cv-00312; 5th Cir. 25-10182
Texas alleges Pfizer misrepresented the vaccine's efficacy, including its advertised 95 percent efficacy figure, in violation of the Texas Deceptive Trade Practices Act. The federal district court dismissed the case; Texas appealed.
The dismissal rested on federal immunity and preemption grounds as reported, not on a finding about the vaccine's safety or efficacy. The appeal is undecided.
Lawsuit allegation Texas files suit in Lubbock County district court (month as reported; the state-court filing is not online). news report
Other public record Pfizer files a notice of removal to federal court (N.D. Tex. No. 5:23-cv-00312, docket entry 1). docket
Court ruling The district court case is terminated after the court dismisses the complaint (reported grounds: PREP Act immunity and federal preemption). docket
Other public record Fifth Circuit dockets Texas's appeal (No. 25-10182). docket
Other public record Fifth Circuit hears oral argument. docket
Revision 2 · status as of Oct 6, 2026 · last checked Nov 11, 2026
litigationLawsuit allegationclosed
ICAN v. CDC (FOIA suits for V-safe data)
Court: U.S. District Court for the Western District of Texas (Austin) · Docket: 1:21-cv-01179; 1:22-cv-00481
FOIA suits that ICAN describes as the litigation that forced CDC to release V-safe data. The structured check-in files were published in 2022; free-text productions followed under FOIA request 24-01322.
The link between these dockets and each V-safe release is as described by ICAN and contemporaneous reporting; the court records establish the cases and their dates.
Lawsuit allegation First FOIA complaint filed (1:21-cv-01179). docket
Lawsuit allegation Second FOIA complaint filed (1:22-cv-00481). docket
Other public record Both cases terminated on the docket. docket
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
litigationCourt rulingclosed
PHMPT v. FDA (FOIA suit for Pfizer vaccine licensing records)
Court: U.S. District Court for the Northern District of Texas (Fort Worth) · Docket: 4:21-cv-01058
A FOIA suit for the records FDA relied on to license Pfizer-BioNTech's vaccine. Judge Mark Pittman ordered production far faster than FDA proposed (reported as 55,000 pages a month rather than 500), which led to the public release of the licensing file.
This is a records-access case. The court ruled on the pace of disclosure, not on the vaccine's safety.
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
litigationLawsuit allegationon appeal
U.S. ex rel. Brook Jackson v. Ventavia Research Group and Pfizer (False Claims Act)
Court: U.S. District Court for the Eastern District of Texas; U.S. Court of Appeals for the Fifth Circuit · Docket: E.D. Tex. 1:21-cv-00008; 5th Cir. 24-40564
A former trial-site regional director alleges protocol violations at Ventavia sites in Pfizer's vaccine trial — including unblinding, inadequate adverse-event follow-up and data-integrity problems — and that the defendants made false claims to the government.
These are the relator's allegations. The district court dismissed the case and the appeal is pending; no court has found the alleged trial misconduct.
Lawsuit allegation Qui tam complaint filed (later unsealed). docket
Court ruling District court case terminated after dismissal. docket
Other public record Fifth Circuit dockets the relator's appeal (No. 24-40564). docket
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
public recordSelf-reported health eventpublished
React19 audit of V-safe free text: "Cries for Help Buried in V-Safe Data" (Brownstone Institute)
React19, an advocacy and support group for people reporting long-term vaccine injuries, keyword-searched the CDC V-safe free-text release (FOIA 24-01322; 7,554,929 responses from 3,489,888 participants, per the audit) for pleas for help, suicidal thoughts, near-death events and deaths. It reports that 3,329 participants met its criteria and submitted 14,430 related entries. Jeffrey Tucker of Brownstone has publicized the compilation.
These counts are React19's, from its own search rules; Drasker has not reproduced them. The audit itself says entries are self-reported, that it does not assess whether a vaccine caused any reported event, and that its counts are a floor.
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
public recordOther public recordreleased
CDC V-safe free-text check-in responses released under FOIA (request 24-01322)
CDC produced the free-text entries V-safe participants typed into check-in surveys in twelve tranches (February 2024 – January 2025) in response to a FOIA request by the Informed Consent Action Network (ICAN), which publishes the files. CDC also produced the structured check-in data (2022), MedDRA codes assigned to free-text responses, and V-safe call-center records.
Drasker does not republish free-text entries, participant IDs or response IDs. Free text can identify people even after redaction; the tracker uses only aggregate counts computed from structured fields.
FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines
FDA approved required labeling changes adding an estimated unadjusted incidence of myocarditis and/or pericarditis after the 2023–2024 formula of mRNA COVID-19 vaccines — about 8 cases per million doses in people 6 months through 64 years old, and about 27 cases per million doses in males 12 through 24 — and results of a cardiac MRI study in which abnormal findings often persisted at about five months.
FDA states that the clinical and prognostic significance of the persistent MRI findings is not known and that longer-term studies are under way.
Revision 2 · status as of Oct 6, 2026 · last checked Nov 11, 2026
regulatory findingOther public recordwithdrawn
FDA revokes the Janssen vaccine's emergency authorization at the company's request
Janssen asked FDA to withdraw the authorization because the last U.S. government lots had expired, there was no demand, and it did not intend to update the vaccine; FDA revoked it.
The stated reasons were commercial and supply-related, not a new safety finding.
CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+
CDC's Vaccine Safety Datalink flagged a possible increase in ischemic stroke 1–21 days after Pfizer's bivalent booster in people 65 and older. Medicare and VA analyses did not find an increased risk, and as data accumulated the agencies said the evidence did not support a safety issue.
A preliminary signal from near-real-time surveillance is not a finding; this one was not confirmed by other systems.
Novavax vaccine authorized with a myocarditis and pericarditis warning
The Novavax fact sheet warns that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis; six cases were detected among 41,546 trial recipients aged 16 and older.
Trial case counts are small; the wording is the regulator's.
FDA limits use of the Janssen (J&J) COVID-19 vaccine because of thrombosis with thrombocytopenia syndrome
FDA limited authorized use of the Janssen vaccine to adults for whom other COVID-19 vaccines were not accessible or clinically appropriate, or who would otherwise not be vaccinated, after determining that the risk of thrombosis with thrombocytopenia syndrome (rare, potentially life-threatening clots with low platelets, with onset about one to two weeks after vaccination) warranted the restriction.
The Janssen vaccine is no longer authorized for use in the United States; this record documents the 2022 regulatory finding.
Revision 2 · status as of Oct 6, 2026 · last checked Nov 11, 2026
regulatory findingOther public recordsuperseded
CDC adopts ACIP's preference for mRNA vaccines over the Janssen vaccine
ACIP recommended mRNA vaccines over the Janssen vaccine for adults, citing the risk of thrombosis with thrombocytopenia syndrome; CDC adopted the recommendation.
Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use
FDA revised the Janssen fact sheets to note an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination; ACIP reviewed the data and concluded benefits outweighed risks.
Superseded by the 2022 restriction and the 2023 revocation of the Janssen authorization.
FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets
FDA revised both mRNA vaccines' fact sheets after ACIP reviewed reports suggesting increased risks of myocarditis and pericarditis, particularly after the second dose and with onset within a few days.
FDA and CDC lift the Janssen pause and add a clotting warning
After two ACIP meetings and a safety review, the agencies lifted the pause and added information about the rare clotting risk to the vaccine's fact sheets.
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
regulatory findingRegulatory safety signallifted
CDC and FDA recommend pausing the Janssen (J&J) vaccine after rare clots with low platelets
CDC and FDA recommended pausing the vaccine “out of an abundance of caution” while reviewing six U.S. reports of cerebral venous sinus thrombosis with thrombocytopenia among more than 6.8 million doses.
A pause to investigate is not a finding that the vaccine caused the events.
Revision 1 · status as of Oct 6, 2026 · last checked Nov 11, 2026
Evidence classes
Self-reported health event
A participant's own report through a monitoring app or survey. Not verified; not a diagnosis; does not establish cause.
Adverse-event report (unverified)
A passive-surveillance report anyone may file (providers, manufacturers, the public). Reports can be incomplete, coincidental or duplicated and do not establish cause.
Medical care reported
A report that the person sought or received medical care (office, urgent care, emergency room). Unverified unless stated.
Hospitalization reported
A report that states hospitalization or prolonged hospitalization. Unverified; does not establish cause.
Life-threatening event reported
A report that states a life-threatening event. Unverified; does not establish cause.
Permanent disability reported
A report that states permanent disability. Unverified; does not establish cause.
Birth defect reported
A report that states a congenital anomaly or birth defect. Unverified; does not establish cause.
Death reported
A report that states the person died. A reported death is not a determination that a vaccine caused it.
Compensation claim filed
A petition or claim filed with a compensation program. Filing is an allegation, not a finding.
Claim compensated
A claim that resulted in payment. Program rules differ; many payments are settlements without a causation finding.
Claim dismissed or denied
A claim the program dismissed or denied, for causation or for procedural reasons.
Lawsuit allegation
A claim made in a complaint or brief. Allegations are not findings of fact.
Court ruling
A ruling or order by a court. Procedural rulings (jurisdiction, removal, preemption) are not findings about vaccine safety.
Regulatory safety signal
A regulator's statement that a possible risk is being evaluated or warrants action.
Recognized adverse reaction
A risk a regulator has added to product labeling or formally recognized.
Epidemiologic association
A statistical association reported by a study with a defined population and denominator.
Causal finding
A formal determination of causation by a study design, regulator, or court that is built to make one.
Other public record
A document or dataset that is part of the public record but is not itself one of the classes above.
Sources, cadence and provenance
CICPactivedata as of Oct 1, 2026
Countermeasures Injury Compensation Program (CICP) — claims data, including COVID-19 vaccines
Publisher: HRSA (U.S. Department of Health and Human Services)
How Drasker gets it: Official HRSA pages (summary and claim tables 1 and 4). hrsa.gov refuses automated clients, so the runner uses the Internet Archive's newest successful capture of each official page; the official URL and the capture URL are both kept.
Update cadence: Monthly (HRSA refreshes the data page monthly; captures can lag).
Denominator: Claim counts have no population denominator.
CICP figures are claims and program decisions. Filing a claim is an allegation, a denial is often procedural (missing records, missed deadline), and a payment is a program determination under the CICP's rules, not a scientific finding that a countermeasure caused an injury. Most COVID-19 claims were still awaiting records or review on the as-of date.
CDC V-safe after-vaccination health checker — structured check-in data (FOIA production)
Publisher: CDC (produced under FOIA; files published by ICAN)
How Drasker gets it: One-time backfill of CDC's structured check-in files as published by ICAN; only check-the-box fields are read and only counts are stored.
Update cadence: Historical dataset (V-safe COVID-19 check-ins ended in 2023). Release list re-checked monthly.
Denominator: Shares use participants who completed at least one check-in in the same file. V-safe enrollment was voluntary and self-selected, so shares describe participants, not everyone vaccinated.
V-safe entries are self-reported, unverified and not diagnoses. Reporting medical care or a missed workday after vaccination does not show the vaccine caused it. Free-text entries are not used or republished.
Vaccine Adverse Event Reporting System (VAERS), via CDC WONDER
Publisher: CDC and FDA (CDC WONDER)
How Drasker gets it: CDC WONDER XML API, aggregate queries only, data-use restrictions accepted on each request, at least 15 seconds between requests. The raw VAERS download page requires a human verification code and is not used.
Update cadence: Checked weekly; ingested when WONDER publishes a new monthly VAERS vintage.
Denominator: None. VAERS does not know how many people were vaccinated, so counts are reports and are never shown as rates.
Anyone can file a VAERS report. Reports are unverified, may be incomplete, coincidental or duplicated, and do not show that a vaccine caused an event. One report can name several vaccines, outcomes and symptoms.
National Vaccine Injury Compensation Program — monthly statistics report
Publisher: HRSA (U.S. Department of Health and Human Services)
How Drasker gets it: Official monthly PDF. hrsa.gov refuses automated clients, so the runner uses the Internet Archive's capture of the same official file when the direct request is refused; both URLs are kept.
Update cadence: Monthly (HRSA updates the report on the first of each month).
Denominator: Petition counts have no population denominator. HRSA's adjudication-category table lists CDC counts of doses distributed (not administered) for 2006–2024; Drasker shows that figure only alongside that table.
VICP figures are petitions and payments, not injury counts. HRSA states that about 60 percent of compensation comes from negotiated settlements in which HHS did not conclude the vaccine caused the injury, and that being compensated does not necessarily mean the vaccine caused the alleged injury. COVID-19 vaccines are not covered by the VICP.